學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Chinese Medicine in an Emerging Market
內容大綱
It was estimated in 2002 that the size of the traditional Chinese medicine (TCM) market in China would be around $5 billion. A decade of Chinese regulatory reforms, Chinese pharmaceutical industry liberalization, changing Chinese lifestyle and demographics, and the Chinese pharmaceutical research and development facilities were factors explaining the huge TCM market potential in China. Multinationals wanting to enter this market might have to deal with inadequate intellectual property protection, corruption in health insurance reimbursement, complex regulatory procedures, and underdeveloped pricing, bidding, and distribution practices.